检索结果 - Toshiyuki Tamai

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses 由 Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, Takuya Suzuki, Takuji Okusaka, Kenji Ikeda, Hiromitsu Kumada

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma 由 Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, Hiromitsu Kumada

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma 由 Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial

    Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial 由 Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma

    Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma 由 Arndt Vogel, Catherine Frenette, Max W. Sung, Bruno Daniele, Ari David Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies 由 Robert J. Motzer, Matthew H. Taylor, T.R. Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M. Lubiniecki, Corina E. Dutcus, Alan D. Smith, Chinyere E. Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker

    出版 2022
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

    REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset 由 Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, Namiki Izumi, Ryosuke Tateishi, Masafumi Ikeda, Hiroshi Aikata, Yasunori Kawaguchi, Yoshiyuki Wada, Kazushi Numata, Yoshitaka Inaba, Ryoko Kuromatsu, Masahiro Kobayashi, Takuji Okusaka, Toshiyuki Tamai, Chifumi Kitamura, Kenichi Saito, Katsuya Haruna, Kiwamu Okita, Hiromitsu Kumada

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study 由 Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong‐Won Park, D. Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study 由 Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean‐Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang‐Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, T.R. Jeffry Evans

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial 由 Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: